NextCure Inc (NXTC NASDAQ) stock market data APIs
$5.5469
-0.08(-1.4%)
as of September 17, 2025
Try our APIs with
free plan!
NextCure Inc Financial Data Overview
Price chart is built with
Anychart
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Prev. Close
5.5469
Open
5.4678
High
5.8386
Low
5.4678
52 wk Range
2.688-19.2
Market Cap
15 160 K
Shares Outstanding
2 676 K
EPS
-11.29
Beta
1.275
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with NextCure Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NextCure Inc data using free add-ons & libraries
Get NextCure Inc Fundamental Data
NextCure Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -61 203 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: -0.425
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NextCure Inc News
New
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-i...
NextCure GAAP EPS of -$11.29
* NextCure press release [https://seekingalpha.com/pr/20194108-nextcure-provides-business-update-and-reports-second-quarter-2025-financial-results] (NASDAQ:NXTC [https://seekingalpha.com/symbol/NXTC...
NextCure (NXTC) Q2 Loss Widens 71%
Key Points GAAP net loss per share was $(11.29) for Q2 2025, missing the consensus GAAP EPS estimate of $(4.62) by a wide margin, mainly due to a $17.0 million up-front license fee. Cash, cash equiva...
NextCure Soars On Encouraging Preclinical Data Of Brittle Bone Disease Drug Candidate
(RTTNews) - Shares of NextCure Inc. (NXTC) are up nearly 30% at $6.60 in premarket trading on Friday, following encouraging preclinical data of its brittle bone disease drug candidate, NC605. Osteoge...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
